119 Significant and comparable increases in anemia-related indicators were observed in both supplemented groups, including blood iron, hemoglobin, and ferritin
No take-back program nearby
Retatrutide works by simultaneously activating three receptors involved in energy regulation and glucose metabolism: GLP-1 receptor agonism reduces appetite, slows gastric emptying, and enhances insulin secretion in a glucose-dependent manner
Patient-derived organoids have also been used for personalized drug screening, offering a promising strategy for precision oncology
Retatrutide is an investigational triple receptor agonist that simultaneously targets the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors
News provided by Novo Nordisk Inc